Advertisement
Ranexa(R) (ranolazine extended-release tablets) is indicated for thetreatment of chronic angina in patients who have not achieved an adequateresponse with other antianginal drugs, and should be used in combination withamlodipine, beta-blockers or nitrates. The product has not been determined byregulatory authorities to be safe and effective for any other use.
Advertisement
About CV Therapeutics
CV Therapeutics, Inc., headquartered in Palo Alto, California, is abiopharmaceutical company focused on applying molecular cardiology to thediscovery, development and commercialization of novel, small molecule drugsfor the treatment of cardiovascular diseases.
CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-releasetablets), is indicated for the treatment of chronic angina in patients whohave not achieved an adequate response with other antianginal drugs, andshould be used in combination with amlodipine, beta-blockers or nitrates.
CV Therapeutics' clinical and preclinical drug development candidates andprograms, including regadenoson, which is being developed for potential use asa pharmacologic stress agent in myocardial perfusion imaging studies, andCVT-6883, which is being developed as a potential treatment forcardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined byany regulatory authorities to be safe or effective in humans for any use.
Except for the historical information contained herein, the matters setforth in this press release, including statements as to treatment guidelines,are forward-looking statements within the meaning of the "safe harbor"provisions of the Private Securities Litigation Reform Act of 1995. Theseforward-looking statements are subject to risks and uncertainties that maycause actual results to differ materially, including operating losses andfluctuations in operating results; capital requirements; regulatory review andapproval of our products; special protocol assessment agreement; the conductand timing of clinical trials; commercialization of products; marketacceptance of products; product labeling; concentrated customer base; andother risks detailed from time to time in CV Therapeutics' SEC reports,including its Quarterly Report on Form 10-Q for the quarter ended June 30,2007. CV Therapeutics disclaims any intent or obligation to update theseforward-looking statements.
SOURCE CV Therapeutics, Inc.
